Frequency Therapeutics Inc
Performance History
| Key Stats | |
|---|---|
| Open | $37.20 |
| Prev. Close | $41.40 |
| EPS | -1.90 |
| Dividend | $0.00 |
| Next Earnings Date | Aug 10, 2023 |
| Dividend Yield % | - |
| Market Cap | $1.37B |
| PE Ratio | - |
| low | high | |
|---|---|---|
| Day Range | 36.83 | 39.04 |
| 52 Week Range | 0.18 | 43.00 |
| Ratios | |
|---|---|
| P/B Ratio | 0.91 |
| Revenue | - |
| Operating M. % | 0.00% |
| Earnings | - |
| Earnings Growth % | - |
| EBITDA Margin % | - |
| ROE % | -99.93% |
| EPS | -1.90 |
Score Breakdown
All Score (49 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| FREQ | Market | |
|---|---|---|
| Value | 22 | 42 |
| Quality | 39 | 46 |
| Ownership | 9 | 39 |
| Growth | 69 | 44 |
| Dividends | - | 32 |
All Score (49 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About Frequency Therapeutics Inc (FREQ)
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
- ISN
- -
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. David L. Lucchino
- Headquarters
- Lexington
- Employees
- 46
Keep an eye on Frequency Therapeutics Inc
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
News
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.